Suppr超能文献

雌激素、选择性雌激素受体调节剂,以及现在的雌激素或雄激素受体的机制特异性配体?

Estrogen, selective estrogen receptor modulators and now mechanism-specific ligands of the estrogen or androgen receptor?

作者信息

Khosla Sundeep

机构信息

Endocrine Research Unit, Division of Endocrinology, Metabolism, and Nutrition, Mayo Clinic and Foundation, 200 First Street SW, 5-194 Joseph, Rochester, MN 55905, USA.

出版信息

Trends Pharmacol Sci. 2003 Jun;24(6):261-3. doi: 10.1016/S0165-6147(03)00124-X.

Abstract

Estrogen, the traditional treatment of both short- and long-term consequences of the menopause, has fallen into disfavor. Thus, selective estrogen receptor modulators (SERMs) have been used as an alternative approach to activate estrogen signaling pathways in a tissue-specific manner. In addition, recent findings indicate that some compounds might activate specific estrogen signaling pathways that are beneficial without affecting other pathways that might lead to the harmful side-effects associated with estrogen. These so-called mechanism-specific ligands of estrogen or androgen receptors hold considerable promise as novel approaches to treat (or at least ameliorate) the consequences of estrogen deficiency.

摘要

雌激素,这种用于治疗更年期短期和长期后果的传统疗法,已失宠。因此,选择性雌激素受体调节剂(SERM)已被用作一种替代方法,以组织特异性方式激活雌激素信号通路。此外,最近的研究结果表明,一些化合物可能激活特定的雌激素信号通路,这些通路有益,同时不会影响其他可能导致与雌激素相关有害副作用的通路。这些所谓的雌激素或雄激素受体的机制特异性配体,作为治疗(或至少改善)雌激素缺乏后果的新方法,具有很大的前景。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验